IL2RA and anaplastic large cell lymphoma: In patients with refractory ALK+ and ALK-negative ALCL, treatment with daclizumab (anti-CD25) has been successful, leading to clinical remission for at least 12 months in ALK+ and 45 months in ALK-negative ALCL, respectively [45,46].